Laddar...
Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab
BACKGROUND: Management of disease-modifying therapies in Multiple Sclerosis (MS) during the COVID-19 pandemic is a controversial issue. Alemtuzumab is an immunosuppressive drug that induces lymphocytes depletion. In this study, we aimed to evaluate the frequency and severity of COVID-19 in a case se...
Sparad:
| I publikationen: | Mult Scler Relat Disord |
|---|---|
| Huvudupphovsmän: | , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Elsevier B.V.
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7286822/ https://ncbi.nlm.nih.gov/pubmed/32554284 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.msard.2020.102297 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|